Senores Pharmaceuticals IPO Financials
The Senores Pharmaceuticals IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 30 Sep 2024, Senores Pharmaceuticals Limited reported assets of ₹678.08 crore, revenue of ₹183.35 crore, and a profit after tax (PAT) of ₹23.94 crore. The company had a net worth of ₹319.06 crore and reserves & surplus of ₹263.36 crore, and total borrowings are 242.03 crore.
Revenue increased by 18.54% in 31 Mar 2024 and decreased by 82.05% in 31 Mar 2023 and decreased by 62.51% in 31 Mar 2022, while Profit After Tax (PAT) grew by 36.63% in 31 Mar 2024 and declined by 74.23% in 31 Mar 2023 and declined by 88.26% in 31 Mar 2022, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Senores Pharmaceuticals Limited Financials (₹ in Crores)
| Particular | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Revenue | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| Net Worth | 319.06 | 231.71 | 45.5 | 36.59 |
| Reserve & Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowings | 242.03 | 248.38 | 60.76 | 14.21 |
EPS Pre
9.83%
EPS Post
13.86%
P/E Pre
39.77
P/E (Post Issue)
28.21x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited reported revenue of ₹183.35 crore as of 30 Sep 2024. Revenue figures from the Senores Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited reported a Profit After Tax (PAT) of ₹23.94 crore as of 30 Sep 2024. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Senores Pharmaceuticals Limited?
Senores Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 39.77x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.